TMCnet News
Immutep's TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual MeetingSYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of eftilagimod alpha (“efti”) has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting, which is taking place as a virtual event from 9-14 November, US Eastern Standard Time (US EST). SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy. Its Annual Meeting is a multidisciplinary educational and interactive conference focused on improving cancer patient outcomes. Immutep’s Poster Presentation:
About TACTI-002 About Immutep Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein which is a first-in-class antigen presenting cell (APC) activator and is being explored in cancer and infectious disease. Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep’s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media: U.S. Media: This announcement was authorised for release by the Chief Executive Officer of Immutep Limited. |